3/A//SEC Filing
Vivo Capital Fund IX, L.P. 3/A
Accession 0001209191-21-022469
CIK 0001789769other
Filed
Mar 21, 8:00 PM ET
Accepted
Mar 22, 8:43 PM ET
Size
7.9 KB
Accession
0001209191-21-022469
Insider Transaction Report
Form 3/AAmended
Vivo Capital IX, LLC
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (11,709,696 underlying)Series C Preferred Stock
→ Common Stock (477,091 underlying)
Vivo Capital Fund IX, L.P.
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (11,709,696 underlying)Series C Preferred Stock
→ Common Stock (477,091 underlying)
Footnotes (2)
- [F1]This Form 3 amendment is being filed to restate this footnote to correct the preferred stock to common stock conversion rate: Each share of Series B Preferred Stock and Series C Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.2 for one basis, has no expiration date and is expected to automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.
- [F2]The securities are held by Vivo Capital Fund IX, L.P. ("Fund IX"). Vivo Capital IX, LLC ("Capital IX") is the general partner of Fund IX. As the managing members of Capital IX, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Fund IX, but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.
Documents
Issuer
Instil Bio, Inc.
CIK 0001789769
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001750117
Filing Metadata
- Form type
- 3/A
- Filed
- Mar 21, 8:00 PM ET
- Accepted
- Mar 22, 8:43 PM ET
- Size
- 7.9 KB